Stavanger

• A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscu … Ended recruitment
  2024-511492-15-00 5 2021-12-09 Duchenne Muscular Dystrophy
• Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended recruitment
  2023-509864-96-00 4 2021-12-07 Mantle Cell Lymphoma (MCL)
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• The REST (Replacing Steroids in the transplant ineligible) study. Ended recruitment
  2023-510194-34-00 4 2021-06-18 Multiple myeloma
• Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Ended recruitment
  2024-510716-71-00 5 2020-10-21 Multiple Sclerosis
• POLAR BEAR Ended recruitment
  2022-502887-19-00 5 2020-08-18 Diffuse Large B-Cell Lymphoma
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• A Phase 3 trial of BCG with or without pembrolizumab for High Risk Non Muscle Invasive Bladder Cancer Ended recruitment
  2022-501817-29-00 5 2018-11-27 High Risk Non-muscle invasive bladder cancer
• A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM … Ended recruitment
  2024-517417-32-00 4 2018-11-22 CHRONIC MYELOID LEUKEMIA
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended recruitment
  2024-517321-99-00 4 2016-08-01 Myeloma multiplex
• PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended recruitment
  2022-501253-37-00 4 2016-02-02 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarcinoma (gallblad
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 4 2025-11-25 Alzheimer's Disease
• A PHASE 1B DOSE RANGE FINDING STUDY OF PHENSERINE COMPARED TO DONEPEZIL IN PARTICIPANTS WITH EARLY OR MILD ALZHEIMER’S DISEASE Ended
  2023-510282-10-00 3 2025-02-11 Mild Cognitive Impairment
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• The TAF-MS study Ended
  2023-503814-62-00 4 2024-02-06 Multiple sclerosis
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended
  2022-501850-12-00 4 2023-03-15 Psoriasis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• Efficacy and safety of UV1 vaccination +/- standard of care as first line treatment of patients with non-small cell lung cancer Ended
  2022-502437-25-00 4 2022-08-15 advanced or metastatic non-small cell lung cancer
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease

Showing 97–120 of 125 trials